TFAP2C and colorectal carcinoma: Kaplan-Meier survival analysis indicated that CRC patients with high TFAP2C expression exhibited shorter overall survivals and progression-free survivals (Fig. 2g and h), which were further verified by the analysis results from several publicly available CRC dataset (Additional file 7: Figure S2A-F).